News From Industry Sources
Study confirms effectiveness of magnetic therapy in pain relief
September 25, 2008 [Source: Gradient Medical]
In a study entitled Optimization of Static Magnetic Field Parameters Improves Analgesic Effect in Mice published in Bioelectrocmagnetics 28: 615-627, 2007, the Hungarian Academy of Science finds multiple static magnetic fields utilizing Gradient Medical's QuadraBloc™ design to be optimal and to have an analgesic effect of greater than 80 percent. Story
New non-prescription nerve pain management treatment available in the U.S.
September 16, 2008 [Source: Origin BioMed]
Origin BioMed recently launched its lead product Neuragen(R) in the United States. Neuragen is the first non-prescription topical homeopathic treatment for rapid relief of diabetic and post-shingles nerve pain. Neuragen is effective in relieving pain in a variety of nerve related conditions. Neuragen works in 5 to 20 minutes and provides up to eight hours of relief. Story
Botox relieves pain caused by migraines
September 16, 2008 [Source: Allergan Inc]
Allergan, Inc. reports that it has completed a top-line analysis of its two Phase III clinical trials exploring the use of BOTOX(botulinum toxin type A) for the prophylactic treatment of headache in adults suffering from chronic migraine - i.e., headaches and/or migraines that occur on 15 or more days each month. In both studies, patients receiving BOTOX(R) treatments scored astatistically significant higher improvement in quality of life vs. patients receiving placebo injections (p less than 0.001 in both studies). Story
Alpharma announces positive results from pivotal phase III efficacy trial on EMBEDA(morphine sulfate extended-release with sequestered naltrexone hydrochloride)
September 09, 2008 [Source: Alpharma Inc]
According to the study findings, patients who were taking ALO-01 capsules reported significantly more effective pain relief, as measured by mean change in the weekly Brief Pain Inventory (BPI) Average Pain Intensity Score from baseline to the 12-week endpoint of the study, compared to patients who were taking placebo. Additionally, 72.5 percent of patients reported taking ALO-01 experienced pain relief of at least 30 percent from baseline, compared to 57.8 percent patients given placebo. Data also suggests that naltrexone did not leak out of the capsules, and there was no increased risk of opioid withdrawal versus placebo. This study was presented in a poster session at the 19th Annual Clinical Meeting of the American Academy of Pain Management in Nashville. Story
New scientific review shows that zolmitriptan ('Zomig(TM)') nasal spray provided efficacious relief from cluster headache
September 8, 2008 [Source: AstraZeneca]
Results from a new pooled data analysis presented at the European Headache and Migraine Trust International Congress (EHMTIC) 2008 today show that zolmitriptan ('Zomig') nasal spray provided fast and efficacious relief in the treatment of episodic and chronic cluster headache. The data shows that zolmitriptan nasal spray provided significant relief from cluster headache at 30 minutes Story
Oral CGRP receptor antagonist showed statistically significant improvement in migraine relief versus placebo
September 8, 2008 [Source: Merck Sharp & Dohme Limited]
Merck Sharp & Dohme Limited announced that in a Phase III clinical trial telcagepant (formerly known as MK-0974) - an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist - significantly relieved moderate-to-severe migraine attacks, including migraine pain and migraine-associated symptoms, compared to placebo. In addition, the overall rates of adverse events in this trial were similar for telcagepant and placebo Story |
